Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

DKTK Essen/Düsseldorf: New findings support immunotherapy of skin cancer

No. 30 | 31/05/2017 | by AM

Merkel cell carcinoma of the skin is often invisible for the body’s immune defense because it silences specific genes of the immune system. Scientists from the German Cancer Consortium (DKTK) at the Medical Faculty of Duisburg Essen University at Essen University Hospital have found a way how to make the tumor a target for the immune system again. Thus, immunotherapeutic approaches in the treatment of skin cancer might become much more effective. In the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ) in Heidelberg joins up as a core center in long-term collaborations with partner university institutes and hospitals all over Germany that are specialized in research and treatment with a focus on oncology.

© Prof. Lorenzo Cerroni /Medizinischen Universität Graz

Immunotherapy is today one of the most promising treatment methods for a number of skin cancers. Various immunotherapeutic approaches are also being used to treat Merkel cell carcinoma, a rare type of skin cancer that is particularly aggressive. However, only about 50 percent of the patients currently benefit from immunotherapy.

The cause for this is to be found in the molecular makeup of the immune system and in the way cancer cells manipulate it. In prior studies, scientists already noticed that in some patients Merkel cell tumors are overseen by the immune defense because they do no present human leukocyte antigens (HLA) on their cell surface. The HLA system plays a key role in humans for the process of labeling cancer cells for destruction by immune cells. 

In the present study, scientists from the German Caner Consortium (DKTK) at Essen University Hospital have been the first to discover the mechanisms that the cancer cells use for their camouflage. The tumor uses so-called epigenetic mechanisms in order to silence genes that are essential for antigen presentation.

“The majority of Merkel cell carcinomas in Europe are caused by infection with the Merkel cell polyoma virus, which strongly manipulates the epigenetics of tumor cells,” said Professor Jürgen Becker, who is last author of the study and head of the DKTK working group “Translational Skin Cancer Research” at Essen University Hospital. “An important chemical label, the histone acetylation, is removed in the reprogrammed cancer cells. This leads to the silencing of various immune genes – a phenomenon that is also known as ‘epigenetic silencing’”. Genes that are involved in the presentation of tumor antigens on the surface of cancer cells are thus being silenced, and the immune system no longer recognizes the tumor cells.

In collaboration with colleagues from the University of Washington and Massachusetts General Hospital in Boston, the scientists have now found two methods to reverse this mechanism. One is to equip the cancer cells with the missing processed antigens. The cancer cells subsequently present them on their surface and are attacked and destroyed by T cells. In further experiments, the researchers blocked the key enzyme that is responsible for the inactivation, histone deacetylase (HDAC). As a result, the genes that are responsible for antigen presentation were reactivated and the tumor cell surfaces were loaded with more HLA again.

“Our results show that the camouflage in Merkel cell carcinoma can be reversed pharmacologically,” said Becker, a physician. He is confident that the new findings will improve clinical outcomes of immunotherapies to treat this type of skin cancer. “First we will test the effectiveness of various combination therapies with clinically applicable HDAC inhibitors. The next goal is to conduct clinical trials with patients for whom immunotherapeutic approaches have been ineffective until now.”

Cathrin Ritter et al.: Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. In: Scientific Reports 2017,


* The German Cancer Consortium (DKTK) is a joint long-term initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ) and was established as one of six German Health Research Centres (DZGs). As DKTK's core center the DKFZ works together with research institutions and hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich, Heidelberg and Tübingen to create the best possible conditions for clinically oriented cancer research. The consortium promotes interdisciplinary research at the interface between basic research and clinical research, as well as clinical trials for innovative treatments and diagnostic methods. Another key focus of the consortium's work is on developing research platforms to speed up the application of personalized cancer treatments and to improve the diagnosis and prevention of cancer.

More information is available at

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS